Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.49 |
| ▸ | KDR | P35968 | 18/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | MST1R | Q04912 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14839976 | 0.92 | MET (0.51) | METKDRNTRK1KITAXL | |
| SCHEMBL14840067 | 0.91 | MET (0.46) | METKDRNTRK1KITAXL | |
| SCHEMBL14840045 | 0.90 | MET (0.49) | METKDRNTRK1KITAXL | |
| SCHEMBL14839803 | 0.90 | MET (0.48) | METKDRNTRK1KITAXL | |
| SCHEMBL1478773 | 0.89 | MET (0.53) | METKDRNTRK1KITAXL | |
| SCHEMBL14839750 | 0.87 | MET (0.52) | METKDRNTRK1KITAXL | |
| SCHEMBL14851405 | 0.83 | MET (0.51) | METKDRNTRK1KITAXL | |
| SCHEMBL14857559 | 0.83 | MET (0.56) | METKDRNTRK1KITAXL | |
| SCHEMBL14839978 | 0.82 | MST1R (0.62) | METKDRNTRK1KITAXL | |
| SCHEMBL172004 | 0.82 | MET (0.70) | METKDRNTRK1KITAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090327-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090327-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | MET 25/4885KDR 1/4885NTRK1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.